Achieve Life Sciences is a late-stage specialty pharmaceutical company centered on cytisinicline, a plant-derived partial agonist of nicotinic receptors for treating nicotine dependence. The drug is designed to ease withdrawal while reducing the reward of smoking or vaping, and has been studied in multiple clinical programs for smoking cessation. The company is advancing cytisinicline toward regulatory approval as a potential new prescription option for adults who want to quit nicotine.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -12.8 | — |
| Q2 2025 | 0 | — | -12.7 | — |
| Q3 2025 | 0 | — | -14.4 | — |
| Q4 2025 | 0 | — | -14.7 | — |
| Q1 2026 | 0 | — | -10.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY), Republic Airways Holdings Inc. (RJET), Apogee Enterprises, Inc. (APOG), Pharming Group N.V. (PHAR), Cryoport, Inc. (CYRX), Southern Missouri Bancorp, Inc. (SMBC)